Butanedioic Acid — Competitive Intelligence Brief

Butanedioic Acid (SUCCINIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin C [EPC]. Area: Hematology.

marketed Vitamin C [EPC] Egl nine homolog 1 Hematology Small molecule

Target snapshot

Butanedioic Acid (SUCCINIC ACID).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Butanedioic Acid TARGET	SUCCINIC ACID		marketed	Vitamin C [EPC]	Egl nine homolog 1
Jesduvroq	DAPRODUSTAT	GSK	marketed	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	Egl nine homolog 1	2023-01-01
Musredo	MOLIDUSTAT	BAYER YAKUHIN, Ltd	marketed		Egl nine homolog 1
Allomaleic Acid	FUMARIC ACID		marketed	Vitamin C [EPC]	Egl nine homolog 1
Enaroy	ENARODUSTAT	Japan Tabacco	marketed		Egl nine homolog 1
Infuvite Adult	alpha-tocopherol acetate	Novartis	marketed	Vitamin C [EPC]		2000-01-01
Glucoferron	FERROUS GLUCONATE	Sanofi	marketed	Vitamin C [EPC]		1999-01-01

Recent regulatory actions (last 90 days)

• 2026-04-09 — Infuvite Adult · FDA · approved · US · Novartis
• 2026-04-09 — Infuvite Adult · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin C [EPC] class)

1. · 16 drugs in this class
2. Pfizer · 5 drugs in this class
3. Energique, Inc. · 2 drugs in this class
4. Exela Pharma · 1 drug in this class
5. Faculdade de Medicina do ABC · 1 drug in this class
6. Glaukos · 1 drug in this class
7. Hippocration General Hospital · 1 drug in this class
8. Jun Gong, MD · 1 drug in this class
9. MEDPOINTE PHARM HLC · 1 drug in this class
10. Novartis · 1 drug in this class